Clinical Trials

Avenue Therapeutics announced that its first pivotal Phase 3 trial of IV tramadol achieved the primary endpoint of a statistically significant improvement in Sum of Pain Intensity…
Read More...

Pfizer announced positive top-line results of a Phase 3 study examining the use of LYRICA (pregabalin) Oral Solution CV as adjunctive therapy for partial onset seizures in pediatric…
Read More...

Albireo Pharma announced the first patient has been enrolled in PEDFIC-1, a Phase 3 clinical trial of lead product candidate A4250, an ileal bile acid transporter (IBAT) inhibitor being…
Read More...

Eli Lilly and Company announced that galcanezumab met its primary endpoint in a Phase 3 study of patients with episodic cluster headache, demonstrating statistically significant…
Read More...

UCB announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the company’s newest anti-epileptic drug (AED) BRIVIACT …
Read More...

Novartis announced that the US Food and Drug Administration (FDA) has approved Gilenya (fingolimod) for the treatment of children and adolescents 10 to less than 18 years of age with…
Read More...

VBI Vaccines announced positive final top-line results from the randomized, placebo-controlled Phase 1 study of VBI-1501, the company’s prophylactic cytomegalovirus (CMV) vaccine…
Read More...

miRagen Therapeutics announced new interim data from its Phase 1 clinical trial of cobomarsen in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL). The…
Read More...

Sylentis, Pharmaceutical Company belonging to the PharmaMar Group, has presented results from the clinical studies carried out with tivanisiran for the treatment of dry eye syndrome and…
Read More...

MenoGeniX announced that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant for…
Read More...

Cirius Therapeutics announced that it has reached its enrollment target in its Phase 2b EMMINENCE trial for its lead program MSDC-0602K in more than 380 patients with NASH and liver…
Read More...

Bioniz Therapeutics announced top-line results from its multiple ascending dose Phase 1b clinical trial of BNZ-1, a novel multi-cytokine inhibitor targeting interleukin (IL)-2, IL-9,…
Read More...

Concert Pharmaceuticals announced that it has completed patient enrollment of its Phase 2a trial evaluating CTP-543 for the treatment of moderate-to-severe alopecia areata. The Company…
Read More...

AstraZeneca and MedImmune announced high-level results from the Phase III ARCTIC trial in patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) who have…
Read More...

NovaDigm Therapeutics announced the initiation of a Phase 2a study evaluating NDV-3A for the reduction of Staphylococcus aureus (S. aureus) colonization in a high-risk population of…
Read More...

Sinovac Biotech Ltd. announced preliminary results of a phase III clinical study on Sabin inactivated polio vaccine developed by Sinovac Biotech on the unblinding conference held on…
Read More...

Evotec AG announced that its multi-target alliance with Bayer has advanced another promising small molecule into Phase I for the treatment of endometriosis, a painful, debilitating…
Read More...

Synlogic announced that it has dosed the first subject in its Phase 1/2a clinical trial of SYNB1618. SYNB1618 is a Synthetic Biotic medicine being developed for the treatment of…
Read More...

ProBioGen AG announced that it has signed a second clinical immuno-oncology development and manufacturing agreement with Tizona Therapeutics, Inc., a privately held immunology company,…
Read More...

Merck announced that the company is beginning two Phase 3 studies of PCV-15 (V114), its investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease. The…
Read More...